Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

Last updated: March 31, 2025
Sponsor: Physio-Assist
Overall Status: Active - Recruiting

Phase

N/A

Condition

Bronchiectasis

Scar Tissue

Treatment

SIMEOX

Remote Physiotherapy

Clinical Study ID

NCT06487273
2023-A01095-40
  • Ages > 18
  • All Genders

Study Summary

Bronchiectasis is a chronic lung disease of multiple aetiologies characterised by permanent dilatation of the calibre of a territory of the bronchial tree with impaired mucociliary clearance. This alteration causes mucus retention, leading to infections and chronic bronchial inflammation. Respiratory physiotherapy is one of the cornerstones of the management of these patients, in particular to facilitate bronchial drainage. In patients with abundant bronchial secretions, it is recommended that bronchial drainage sessions be carried out on a daily or more frequent basis, which represents a very substantial burden in terms of care. In addition, access to respiratory physiotherapy is not always easy for patients due to geographical or time constraints or the availability of professionals. Moreover, few professionals are trained in this specific care for chronic lung diseases.

SIMEOX (Physio-Assist, France) is an innovative medical device (CE medical mark) for draining the bronchial tree. By means of a mouthpiece, this device generates a succession of very short intermittent negative air pressure pulses which disseminate a pneumatic vibratory signal in the patient's bronchial tree, modifying the rheological properties of the mucus, facilitating the mobilisation of secretions and assisting their transport towards the upper airways.

A recent pilot study demonstrated that the use of SIMEOX independently by the patient at home for 3 months, combined with remote Physiotherapy (1 session/2 weeks), provided a very satisfactory bronchial drainage solution for patients (satisfaction assessed at 9/10 by visual analogue scale), with an improvement in their quality of life and very good compliance with the device (median of 4.7 sessions/week).

This bronchial drainage strategy requires a long-term assessment.

Hypothesis: the use of SIMEOX independently by the patient at home could improve long-term quality of life and reduce the rate of pulmonary exacerbations in non-cystic fibrosis (non-CF) patients with bronchiectasis (bronchial dilatation) in comparison to Standard of Care (SoC).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female aged over 18 years

  • Predominant diagnosis of Non CF bronchiectasis disease, excluding cystic fibrosis,confirmed by computed tomography (CT).

  • Regular and chronic sputum production

  • Clinically stable at inclusion

  • Defined by a delay of at least 4 weeks since the end of the last exacerbationaccording to the European consensus (Hill, European Respiratory Journal, 2017)

  • No change in disease-modifying treatment for 4 weeks.

  • Having had at least two pulmonary exacerbations in the 12 months prior to inclusionand having required a change in specific treatment for these exacerbations.

Or Having had at least one pulmonary exacerbation in the 12 months prior to inclusion requiring hospitalisation.

  • Considered by the investigator to be physically and psychologically able to use thedevice and carry out the procedures under study.

  • Patient covered by a social security system, when applicable in the concernedcountry

Exclusion

Exclusion Criteria:

  • Patients using one of the following motorised mechanical bronchial drainage devicesat home at the time of inclusion:

  • SIMEOX,

  • an extra-thoracic high-frequency chest wall oscillation device (HFCWO) (TheVest,...)

  • intrapulmonary percussion ventilation (IPV)

  • Patients who have been using a powered mechanical cough aid at home for less than ayear at the time of inclusion:

  • a mechanical in-exsufflator (MI E) such as the Cough Assist

  • a pressure reducer such as the Alpha300

  • Cystic fibrosis

  • Predominant diagnosis of Chronic obstructive pulmonary disease (COPD) or asthma,traction bronchiectasis, bronchiectasis resulting from focal endobronchial lesion,sarcoidosis or active allergic bronchopulmonary aspergillosis.

  • Active smoking

  • Suspected (but undiagnosed) or unstabilised immune deficiency (at investigator'sdiscretion)

  • In the case of long-term immunosuppressive treatment, risk of discontinuation ofthis treatment during the study.

  • Unstable cardiovascular pathologies (acute coronary syndrome, unstable anginapectoris, uncontrolled rhythm disorders, unstable heart failure)

  • Haemodynamic instability

  • Uncontrolled gastro-oesophageal reflux (persistence of symptoms despite treatment),at investigator's discretion.

  • Acute pneumothorax or increased susceptibility to pneumothorax/pneumomediastinum

  • Inability to cough vigorously and independently, at investigator's discretion

  • Had a significant episode of haemoptysis in the 6 weeks prior to inclusion, at thediscretion of the investigator

  • Patient using an endotracheal tube, tracheostomy tube or daytime ventilation >16hwith a mask

  • Patients with neuromuscular disease and respiratory muscle weakness, at thediscretion of the investigator

  • Recent cardiothoracic surgery, including oesophageal surgery within 3 months ofinclusion

  • Severe acute lung injury or barotrauma within 3 months of inclusion

  • Difficulty in evacuating secretions from the upper airways due to weakness of therespiratory muscles, or of the oropharyngeal or buccal musculature, at thediscretion of the investigator

  • Risk of airway aspiration, e.g. from tube feeding or recent meals, at investigator'sdiscretion

  • Inspiratory muscle weakness with inability to tolerate increased work of breathing,at investigator's discretion

  • Severe restrictive disease (Forced Vital Capacity < 60% or Total Lung Capacity < 60%with complete plethysmography)

  • Bullous emphysema

  • Participation in other interventional clinical study in the month prior to inclusionor during the study period

  • Patient unavailable or wishing to move to a region where the protocol is not presentbefore the end of their participation

  • Vulnerable people:

  • pregnant women (verified by a urine or blood human chorionic gonadotropin (HCG)test for all women wishing to participate in the protocol and of childbearingage, without contraception), breastfeeding mothers or women planning to becomepregnant during the period of participation in the clinical investigation

  • a person deprived of liberty by judicial or administrative decision

  • a person subject to a legal protection measure

Study Design

Total Participants: 622
Treatment Group(s): 2
Primary Treatment: SIMEOX
Phase:
Study Start date:
February 01, 2025
Estimated Completion Date:
December 31, 2027

Study Description

Two main objectives will be assessed simultaneously:

  • To compare the effect of SIMEOX, combined with remote Physiotherapy, with enhanced SoC (SoC + Remote Physiotherapy), on the quality of life related to the respiratory problems of patients at mid term.

  • To compare the effect of SIMEOX, combined with remote Physiotherapy with enhanced SoC (SoC + Remote Physiotherapy) on the rate of respiratory exacerbations at long term.

Connect with a study center

  • CH Abbeville

    Abbeville,
    France

    Active - Recruiting

  • CH Aix en Provence

    Aix-en-Provence,
    France

    Active - Recruiting

  • CHU Amiens Picardie

    Amiens,
    France

    Active - Recruiting

  • Clinique Victor Pauchet

    Amiens, 80090
    France

    Active - Recruiting

  • CHU Angers

    Angers, 49033
    France

    Active - Recruiting

  • CHRU Brest

    Brest, 29200
    France

    Active - Recruiting

  • CH Compiègne

    Compiègne,
    France

    Active - Recruiting

  • CH Compiègne-Noyon

    Compiègne, 60200
    France

    Site Not Available

  • CH Alpes-Léman

    Contamine-sur-Arve, 74130
    France

    Active - Recruiting

  • CHI Créteil

    Créteil, 94000
    France

    Active - Recruiting

  • CHU Grenoble-Alpes

    Grenoble, 38043
    France

    Active - Recruiting

  • Groupe Hospitalier La Rochelle - Ré-Aunis

    La Rochelle,
    France

    Site Not Available

  • Hôpital Bicêtre (AP-HP)

    Le Kremlin-Bicêtre, 94270
    France

    Active - Recruiting

  • CH Le Puy-en-Velay

    Le Puy-en-Velay, 43000
    France

    Active - Recruiting

  • CH Libourne

    Libourne, 33500
    France

    Site Not Available

  • HCL- Hôpital Croix-Rousse

    Lyon, 69004
    France

    Active - Recruiting

  • Groupe Hospitalier du Havre

    Montivilliers,
    France

    Active - Recruiting

  • Montpellier Hospital Center

    Montpellier, 34090
    France

    Active - Recruiting

  • CHU Nice

    Nice, 06002
    France

    Active - Recruiting

  • CHU Nîmes

    Nîmes, 30900
    France

    Active - Recruiting

  • Hôpital Cochin (AP-HP)

    Paris, 75014
    France

    Active - Recruiting

  • CH Pau

    Pau, 64000
    France

    Active - Recruiting

  • CHU Poitiers

    Poitiers, 86021
    France

    Active - Recruiting

  • CHU Reims

    Reims, 51092
    France

    Active - Recruiting

  • CHU Rennes

    Rennes, 35033
    France

    Active - Recruiting

  • Fondation Ildys

    Roscoff, 29684
    France

    Active - Recruiting

  • CHU Rouen

    Rouen,
    France

    Active - Recruiting

  • Hôpital Foch

    Suresnes,
    France

    Active - Recruiting

  • CH Tarbes Lourdes

    Tarbes,
    France

    Active - Recruiting

  • CHU Toulouse

    Toulouse,
    France

    Active - Recruiting

  • CH Troyes

    Troyes,
    France

    Active - Recruiting

  • CH Bretagne Atlantique

    Vannes,
    France

    Active - Recruiting

  • CHU La Réunion Félix Guyon

    Saint-Denis,
    Réunion

    Active - Recruiting

  • CHU La Réunion Sud

    Saint-Pierre,
    Réunion

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.